Paradoxical reaction to etanercept: development of pyoderma gangraenosum during therapy of psoriasis arthritis.
Lutz
L
Kowalzick
Julia
J
Bertolini
Christine
C
Baumann
Beate
B
Walther
Beate
B
Truhm
Lena
L
Eickenscheidt
D000293:Adolescent; D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use; D015535:Arthritis, Psoriatic / Q000150:complications* / Q000188:drug therapy*; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects* / Q000627:therapeutic use*; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D017511:Pyoderma Gangrenosum / Q000139:chemically induced* / Q000473:pathology*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D016896:Treatment Outcome
D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept